Medicus Pharma Advances Newly Acquired Program Teverelix in Prostate Cancer and Urology
Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current hormone therapies for prostate cancer and benign prostatic hyperplasia (BPH). Teverelix is a…